Argireline

Acetyl Hexapeptide-8

Argireline (Acetyl Hexapeptide-8) is a healing & recovery research compound. Topical anti-wrinkle peptide — inhibits SNARE-complex assembly to reduce muscle micro-contractions that form expression lines.

How Argireline works

Topical anti-wrinkle peptide — inhibits SNARE-complex assembly to reduce muscle micro-contractions that form expression lines.

Proposed benefits

'Topical Botox-like' softening of expression lines (cosmetic).

Where to get Argireline

The evidence for Argireline

Graded by what exists behind each claim.

✅ Clinically validated

• Controlled topical studies exist and are modest — published work reports reductions in wrinkle depth of roughly 15–30% over several weeks in small trials, most funded by the ingredient manufacturer.

📊 Correlative data

• Extremely wide cosmetic use as the 'topical Botox' ingredient. Real-world reports are consistently underwhelming relative to the marketing, which the mechanism explains.

🧪 Theoretical / extrapolated

• Acetyl hexapeptide-8, a fragment mimicking the SNAP-25 protein that botulinum toxin cleaves — it competitively interferes with SNARE complex formation and so reduces neurotransmitter release at the neuromuscular junction.
• The mechanism is real and the delivery problem is fatal to it: the peptide must reach the neuromuscular junction beneath the dermis, and a hydrophilic hexapeptide applied to intact skin largely does not. That gap is why the effect sizes are small.

How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →

What Argireline actually does

Argireline is acetyl hexapeptide-8, and its full chemical name gives the whole mechanism away: acetyl-glutamyl-glutamyl-methionyl-glutaminyl-arginyl-argininamide Kluczyk 2021. In one-letter form that is Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2, acetylated at the front and amidated at the back.

Those six residues are a copy of a specific piece of a specific protein. Human SNAP-25 begins Met-Ala-Glu-Asp-Ala-Asp-Met-Arg-Asn-Glu-Leu-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-Gln, and the bolded stretch is residues 12 to 17. Argireline is that hexapeptide with both ends capped. It is not inspired by SNAP-25; it is a literal excerpt from it.

Why copying that stretch does anything. Neurotransmitter release requires a four-helix SNARE bundle to zip together: syntaxin-1A and SNAP-25 on the nerve terminal membrane, VAMP-2 on the vesicle. SNAP-25 contributes two of the four helices, and its N-terminal region is part of that assembly. A free peptide with the same sequence competes for the position SNAP-25’s own N-terminus should occupy, so the bundle assembles less efficiently, fewer vesicles fuse, and less acetylcholine reaches the muscle. That is the published description of the mechanism: inhibition of neurotransmitter release at the neuromuscular junction, producing a botulinum-like effect without a needle Kluczyk 2021.

And here is the difference between this and botulinum toxin that decides everything downstream. Botulinum toxin type A is a protease. One molecule enters a nerve terminal and cleaves SNAP-25 molecule after SNAP-25 molecule, catalytically, for months. Argireline is a stoichiometric competitor: one peptide molecule blocks one site, once, and then it is a molecule sitting in a complex. An enzyme works at concentrations thousands of times below those a competitive inhibitor needs, because turnover does the amplifying. So a topical SNARE-competing peptide has to arrive at the junction in quantities comparable to SNAP-25 itself, and the arithmetic for whether it can is in the pharmacokinetics section on this page.

The chemistry, computed rather than quoted. Ac-EEMQRR-NH2 is 889.0 Da, isoelectric point 8.30, and a net charge of about 0.00 at blood pH — the two arginines cancel the two glutamates exactly, and the acetyl and amide caps remove both terminal charges. At the skin surface, around pH 5, it carries about +0.22. So this molecule is close to electrically neutral wherever it sits, which is the most favorable charge state it could have for crossing a lipid barrier — and it is still described as having limited permeability through the stratum corneum on account of its hydrophilic character and its size Zdrada-Nowak 2025.

One liability is built into the sequence. Position 3 is a methionine, the residue that oxidizes to the sulfoxide on contact with air, light or trace metal. Reversed-phase HPLC/MS analysis of commercial creams and serums confirmed the peptide’s presence and identified the methionine as the oxidation point, with oxidized forms detected in several cosmetic products Kluczyk 2021. That is not a theoretical shelf-life concern; it was found in product on sale.

Cell, rodent, human — and where it stops

Step one, analytical chemistry. The peptide is detectable and quantifiable in finished cosmetic creams and sera by reversed-phase HPLC/MS and MS/MS, and the sample preparation had to be built specifically to stop the methionine oxidizing during the analysis itself Kluczyk 2021.

Step two, the barrier, stated by the review that exists for exactly this question. A 2025 review dedicated to acetyl hexapeptide-8 in cosmeceuticals concludes that its hydrophilic nature and relatively large molecular size limit permeability through the lipophilic stratum corneum Zdrada-Nowak 2025. Note what is not in that review: a permeability coefficient, a flux, or a depth profile. The field’s summary statement about the central question is qualitative.

Step three, in humans, with the peptide as the only active. 19 women, a facial serum containing triple hyaluronic acids plus Argireline, 4 weeks, wrinkles measured objectively with the Visia complexion analysis camera. Result: the wrinkle score decreased slightly on both sides of the face and the decrease was not significant, P > 0.05 Henseler 2023. That is the cleanest single-active test of this ingredient in the indexed literature and it is null.

Step four, in humans, with the barrier physically removed — and this is the informative one. 52 Korean women enrolled, 50 completed (96.2%), a cross-linked hyaluronic acid microneedle patch carrying acetyl hexapeptide-8 or epidermal growth factor, applied weekly for 4 hours over 29 days. Wrinkle and skin hydration improved significantly in all groups (P < 0.01), and the combination formulations beat the patch alone (P < 0.05) An 2019.

Read those two studies together, because between them they say the thing this ingredient’s marketing does not. Applied to intact skin as the only active, four weeks produced nothing measurable. Delivered through microneedles that puncture the stratum corneum, it added a measurable amount on top of a patch that already worked on its own. The variable that changed between them is the barrier.

Step five, in humans, with a large effect and five actives. An ex vivo skin study plus two clinical studies — n = 50 for static wrinkles over 12 weeks and n = 42 for dynamic wrinkles — of a serum containing acetyl hexapeptide-8 together with dipeptide diaminobutyroyl benzylamide diacetate, gluconolactone, niacinamide and laminaria extract. Reported improvements: static wrinkles 35% to 69%, dynamic wrinkles 10–13%, smoothness 30%, radiance 27%, pore 43%, elasticity 33%, firmness 36%, all P < 0.001, with ex vivo changes in MMP-1, elastic fibers and collagen types I, III, IV and XVII Zhu 2026.

Those are impressive numbers and they cannot be assigned to this peptide. Gluconolactone is a polyhydroxy acid with its own exfoliating effect on texture and radiance; niacinamide has its own literature on pores, elasticity and barrier; the second peptide in the formula is a separate active with its own page in this Vault. A five-active serum improving pore size by 43% tells you about the serum. It is not evidence about acetyl hexapeptide-8, and the study does not claim to be.

The obstacles, one at a time. (1) The single-active human study was null at 4 weeks in 19 people Henseler 2023. (2) The large-effect study used five actives Zhu 2026. (3) The study that worked best bypassed the stratum corneum with needles An 2019. (4) No permeability coefficient or depth profile has been published for the molecule on human skin Zdrada-Nowak 2025. (5) The mechanism’s target — a neuromuscular junction — is millimetres below the surface, not micrometers.

Argireline pharmacokinetics — how much of it actually gets in

The card says ‘N/A (topical)’, which is true and is where every page on this ingredient stops. Here is the arithmetic instead.

Step 1 — what is actually in the bottle. A label saying ‘10% Argireline’ is quoting the percentage of the supplier’s premix, which is a dilute aqueous-glycol solution of the peptide, not 10% peptide. The pack does not publish the dilution. Real peptide content across the market plausibly spans about 0.05% to 0.5%, and everything below is calculated across that whole range so the answer does not depend on guessing which end a given product sits at.

Step 2 — how much product goes on. The standard application density for topical testing is 2 mg/cm², and a whole adult face is roughly 400 cm². So one application is about 800 mg of product.

Step 3 — how much peptide that is. At 0.5% actual peptide: 10 µg/cm², or 4.0 mg across the whole face. At 0.05%: 1 µg/cm², or 0.4 mg. In molar terms, at 889.0 Da, the high end is 11.25 nmol/cm² sitting on the surface.

Step 4 — how much gets past the stratum corneum. This is the number nobody has measured for this molecule Zdrada-Nowak 2025, so bound it generously rather than invent it. For a hydrophilic peptide of 889 Da — well over the 500 Da rule of thumb for passive percutaneous absorption — a 1% fraction crossing into the viable epidermis is an optimistic upper bound. That gives 0.1 µg/cm² at the top of the concentration range.

Step 5 — what concentration that makes where it lands. The viable epidermis is about 100 µm deep, so one square centimetre of it is about 10 µL of tissue. 0.1 µg in 10 µL is 10 µg/mL, which at 889 Da is about 11 µM. At the bottom of the range, and at a more realistic 0.1% penetration, it is about 0.1 µM. So the honest answer is a low-micromolar-to-sub-micromolar concentration, in the epidermis.

Step 6 — and this is the step that decides it. The target is not in the epidermis. Acetylcholine release happens at the neuromuscular junctions of the facial mimetic muscles, which sit below the dermis — on the order of 1 to 4 millimetres down, which is ten to forty times deeper than the layer the arithmetic above delivers into. Botulinum toxin is injected to that depth for exactly this reason. Every further millimetre costs another large fraction of the dose to dilution and to binding on the way.

The steelman, because it is real and almost nobody states it. Facial mimetic muscles are anatomically unusual: unlike limb muscles they insert directly into the dermis, which is what allows them to move skin. So the distance from a topical film to the shallowest fibers of orbicularis oculi is smaller than the general argument above implies. That is the strongest available case for this ingredient, it is anatomical rather than pharmacological, and no study has measured peptide concentration at that depth in a person.

Systemic exposure, for completeness. Even taking the optimistic 1% crossing figure, whole-face daily use delivers about 40 µg of peptide past the barrier per day, into a body with a plasma volume of about 3 liters and a full complement of peptidases. There is no meaningful systemic pharmacology to discuss and no oral, intravenous or subcutaneous pharmacokinetic study of this molecule exists in any species.

What would have to be true, and how you would know it was not

Four predictions, and the marker vocabulary that governs the rest of this site has no dermatological instrument in it, so the primary read-out here is symptomatic and photographic.

What to watch. Two photographs, not one: the crow’s feet at rest and at maximum smile, at fixed distance, fixed lighting, same lens, same time of day, at week 0, week 6 and week 12. They respond to different things — the resting line is hydration, dermal matrix and light; the dynamic line is muscle. A SNARE-competing peptide is claiming the dynamic one, so a change confined to the resting photograph is not evidence for this mechanism. If an instrument is available, Visia-type imaging is what the null 4-week study used Henseler 2023 and a corneometer reading from the same cheek spot is the hydration control.

How long before it means anything. Twelve weeks. Four weeks produced no significant change in the one single-active trial Henseler 2023; the studies reporting large effects ran 12 weeks Zhu 2026. Anything visible in the first fortnight is the humectant in the base.

What will fool you. Three things, in order of how often they do it. The vehicle — hyaluronic acid plumps the resting line within hours and every published positive result for this ingredient is peptide-in-a-base against something. The other actives — the 12-week study with the big numbers contained five, including a polyhydroxy acid and niacinamide Zhu 2026. And the season: skin photographed in February and again in May has changed for reasons that have nothing to do with the bottle.

Prediction 1, and it cuts against the product. Run the identical base with and without the peptide on left and right sides of the face. At week 4 the two halves will be indistinguishable by camera and by corneometer — that is precisely the comparison the 19-woman study effectively made, and it found P > 0.05 Henseler 2023.

Prediction 2, which follows from the arithmetic and would settle the mechanism. Delivery that breaches the stratum corneum should beat topical application of the same peptide by a wide margin, because the barrier is the rate-limiting step rather than the receptor interaction. The microneedle study is the existing hint An 2019. The clean version is the same peptide, same dose, one side by microneedle patch and one side as a serum, twelve weeks. If topical matches the patch, the whole permeability argument on this page is wrong.

Prediction 3. Nothing in blood moves. Whole-face daily use delivers on the order of tens of micrograms past the barrier per day, against a body that clears peptides continuously, so hs-CRP, a CMP and a CBC should all be flat across a 12-week course. If a blood marker does move, something else in the routine caused it.

What nobody has tested yet

Five experiments. The first two are cheap and would replace the entire qualitative literature on this ingredient with numbers.

1. Nobody has tape-stripped human skin after a real product. Sequential tape strips plus mass spectrometry, on volunteers, after a normal application at a stated peptide concentration, would produce the first depth profile this molecule has ever had. The dedicated review of its skin permeability contains no such number Zdrada-Nowak 2025 and the analytical method needed already exists Kluczyk 2021.

2. Nobody has published how much of the peptide on the shelf is still intact. Oxidized forms were detected in several cosmetic products Kluczyk 2021 — but not quantified as a proportion, and not tracked against time or storage. A survey of twenty products for the intact-to-sulfoxide ratio would tell buyers whether the percentage on the label bears any relation to the active they receive.

3. Nobody knows whether the methionine sulfoxide form is active. Oxidation converts a hydrophobic thioether side chain into a strongly polar sulfoxide in the middle of a six-residue recognition sequence. Whether the oxidized peptide still competes in the SNARE complex is unanswered, and it is a single cell-free binding assay.

4. Nobody has run the peptide alone at 12 weeks in adequate numbers. The 12-week studies used multi-active formulations Zhu 2026; the single-active study ran 4 weeks in 19 people Henseler 2023. A split-face, single-active, 12-week trial in fifty people is an ordinary dermatology study and it has never been published for the most famous cosmetic peptide in the world.

5. Nobody has measured whether any of it reaches muscle. The mechanism is neuromuscular Kluczyk 2021; the delivery is epidermal. Mass spectrometry imaging of a full-thickness biopsy after chronic topical use would say whether the peptide is present at the depth its own mechanism requires. That measurement does not exist for this molecule in any species.

Argireline — its own safety story, not its class's

The class block on this page is written for injectable peptides. None of it applies. Five things below are this ingredient’s own.

1. The main risk is not toxicity, it is buying an oxidized product. Methionine at position 3 is the oxidation point and oxidized forms have been found in commercial products Kluczyk 2021. Nothing on a pack distinguishes an intact peptide from a sulfoxide, the proportion is unpublished, and the sulfoxide is of unknown activity. This is a value problem more than a hazard, and it is real and documented rather than hypothetical.

2. Systemic toxicity is not the question here, and the arithmetic says why. Whole-face daily use puts on the order of tens of micrograms of peptide past the barrier per day, at the optimistic end of the estimate. There is no plausible systemic pharmacology at that exposure, which is also why every claim of a systemic benefit from a topical peptide should be dismissed on arithmetic before it is dismissed on evidence.

3. Irritation belongs to the base, not usually to the peptide. The molecule is small, near-neutral at skin pH (+0.22 computed at pH 5) and water-soluble. The stinging people report from ‘peptide serums’ is far more often the glycols, preservatives or acids they are formulated with — note that the best-performing multi-active study in this file contained gluconolactone, a polyhydroxy acid Zhu 2026.

4. A microneedle patch is a different exposure, not a stronger cream. The patch study delivered the peptide through the stratum corneum into viable tissue An 2019. That converts a cosmetic surface application into a dermal one, with a wound, a sterility requirement and an unknown intradermal dose. It is the delivery route the mechanism argues for, and it is not covered by the safety reasoning that applies to a serum.

5. The one genuinely dangerous version of this ingredient is the injectable one. Preparations of acetyl hexapeptide-8 are sold for injection on the strength of the ‘needle-free botox’ framing Kluczyk 2021. There is no pharmacokinetic study, no systemic safety study and no clinical trial of this peptide by any injected route in any species, and its stated mechanism is inhibition of neurotransmitter release. Injecting a compound whose entire evidence base is topical, near facial muscle, on the reasoning that it works better if you skip the skin, has nothing behind it at all.

Sources read for this page

• Kluczyk A, et al. Argireline: Needle-Free Botox as Analytical Challenge. Chemistry and Biodiversity 2021 · PMID 33482052
• Zdrada-Nowak J, et al. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. International Journal of Molecular Sciences 2025 · PMID 40565185
• Henseler H. Investigating the effects of Argireline in a skin serum containing hyaluronic acids on skin surface wrinkles using the Visia Complexion Analysis camera system for objective skin analysis. GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW 2023 · PMID 38024099
• An JH, et al. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Annals of Dermatology 2019 · PMID 33911590
• Zhu M, et al. The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies. International Journal of Cosmetic Science 2026 · PMID 41668671

Argireline — safety, predicted from mechanism

Argireline — interference & stacking

Bloodwork to run alongside Argireline

Baseline first, then again at 8–12 weeks.

The Inflammation Deep Dive panel covers these in one order — 10 markers, $248.35 with the discount applied.

Check results you already have → · All 103 markers A–Z

Argireline — frequently asked questions

Argireline inside a finished plan

One arm of 1 Protocol Blueprint, free to read in full.

What Argireline is used for

Argireline appears under 1 goal in the goal router.

Related Healing & Recovery compounds

← Explore the full Protocol Vault

↑ Back to on this page